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1. Introduction 
The pathological hallmarks of Parkinson’s disease (PD) are marked loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNc), which causes dopamine depletion in 
the striatum, and the presence of intracytoplasmic inclusions known as Lewy bodies in the 
remaining cells. It remains unclear why dopaminergic neuronal cell death and Lewy body 
formation occur in PD. The pathological changes in PD are seen not only in the SNc but also 
in the locus coeruleus, pedunculo pontine nucleus, raphe nucleus, dorsal motor nucleus of 
the vagal nerve, olfactory bulb, parasympathetic as well as sympathetic post-ganglionic 
neurons, Mynert nucleus, and the cerebral cortex (Braak et al. 2003). Widespread 
neuropathology in the brainstem and cortical regions are responsible for various motor and 
non-motor symptoms of PD. Although dopamine replacement therapy improves the 
functional prognosis of PD, there is currently no treatment that prevents the progression of 
this disease. 
Previous studies provided possible evidence that the pathogenesis of PD involves complex 
interactions between environmental and multiple genetic factors. Exposure to the 
environmental toxin MPTP was identified as one cause of parkinsonism in 1983 (Langston & 
Ballard 1983). In addition to MPTP, other environmental toxins, such as the herbicide 
paraquat and the pesticide rotenone have been shown to contribute to dopaminergic 
neuronal cell loss and parkinsonism. In contrast, cigarette smoking, caffeine use, and high 
normal plasma urate levels are associated with lower risk of PD (Hernan et al. 2002). 
Recently, Braak and coworkers proposed the “Dual Hit” theory, which postulated an 
unknown pathogen accesses the brain through two pathways, the nose and the gut (Hawkes 
et al. 2007). Subsequently, a prion-like mechanism might contribute to the propagation of α-
synuclein from the peripheral nerve to the central nervous system (Angot et al. 2010).  
Approximately 5% of patients with clinical features of PD have clear familial etiology. 
Therefore, genetic factors clearly contribute to the pathogenesis of PD. Over the decade, 
more than 16 loci and 11 causative genes have been identified, and many studies have shed 
light on their implication in, not only monogenic, but also sporadic forms of PD. Recent 
studies revealed that PD-associated genes play important roles in cellular functions, such as 
mitochondrial functions, the ubiquitin-proteasomal system, autophagy-lysosomal pathway, 
and membrane trafficking (Hatano et al. 2009). In this chapter, we review the investigations 
of environmental and genetic factors of PD (Figure 1).  
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Fig. 1. Although the etiology of Parkinson disease (PD) remains unknown, 5-10% of patients 
have clear familial etiology, which show a classical recessive or dominant Mendelian mode 
of inheritance. On the other hand, MPTP or a combination of maneb and paraquat are 
environmental risk factors for PD. Several PD-related genetic factors (e.g., SNPs in ┙-
synuclein) have been discovered, and the interaction between genetic and environmental 
factors might contribute to sporadic PD.  
2. Environmental factors and PD 
2.1 1-methyl-4phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) 
Langston et al reported on four patients who developed typical parkinsonism after repeated 
injection of MPTP intravenously (Langston & Ballard 1983). Furthermore, these patients 
responded to treatment with levodopa and bromocriptine and experienced motor 
fluctuations, similar to patients with idiopathic PD. Interestingly, fluorodopa positron 
emission tomography (FD-PET) study of subjects exposed to MPTP demonstrated that 
transient exposure to this toxin could lead to progressive nigral degeneration (Vingerhoets 
et al. 1994). Neuropathological findings of 3 subjects with MPTP-induced parkinsonism 
showed moderate to severe dopaminergic neuronal degeneration without Lewy bodies in 
the substantia nigra. Interestingly, there was gliosis; clustering microglia around nerve cells 
and extraneural melanin. These findings indicated active and continuing neuronal cell 
degeneration (Langston et al. 1999). PET and neuropathological studies suggested that an 
active neuronal cell death process was persistent for years after these subjects were exposed 
to MPTP. MPTP is a by-product of the chemical synthesis of a narcotic meperidine analog. 
This chemical agent is highly lypophilic, therefore it quickly crosses the blood-brain barrier 
and converts to 1-methyl-4-phenyl-2,3-dihydropyridinium ion (MPP+), which is the active 
toxic compound, via monoamine oxidase B within nondopaminergic cells, such as glial cells 
and serotonergic neurons. MPP+ is transported into dopamine neurons by the dopamine 
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transporter, and therefore exhibits selective toxicity to dopaminergic neurons. Furthermore, 
MPP+ accumulates in mitochondria, where it inhibits the mitochondrial electron transport 
chain component complex I (Przedborski & Vila 2003). Mizuno et al reported that MPP+ 
inhibited the ┙-ketoglutarate dehydrogenase complex of the mitochondrial tricarboxylic 
acid cycle, which synthesizes succinate from α−ketoglutarate (Mizuno et al. 1987). In SNc of 
sporadic PD subjects, decreased activity and protein levels of complex I have also been 
reported (Schapira et al. 1989). Thus biochemical changes in dopaminergic neuronal 
degeneration in sporadic PD were essentially similar to those of subjects exposed to MPTP.  
2.2 Pesticides 
Epidemiological studies have suggested the association between PD and exposure of 
pesticides such as rotenone and paraquat. Rotenone is a potent and high-affinity specific 
inhibitor of complex I. In rodents, continuous infusion of these toxic agents induced 
dopaminergic neuronal cell death and inclusion bodies, which were similar to Lewy bodies 
in PD patients (Betarbet et al. 2000). Therefore, both MPTP and rotenone disrupt 
mitochondrial function and play important roles in the nigral cell degeneration in PD.  
Paraquat, which is a member of a chemical class known as bipyridyl derivatives, is one of 
the most commonly used pesticides, and leads to oxidative and nitrative stress (Berry et al.). 
The chemical structure of paraquat is similar to MPP+. Epidemiologic studies implicate the 
association between exposure to this toxin and the development of PD. Interestingly, recent 
studies revealed that exposure to a combination of paraquat and maneb, which is also 
widely used as an agricultural pesticide, exacerbate dopaminergic degeneration in the 
rodent model and cause an increased incidence of PD in humans (Costello et al. 2009). In 
this context, exposure to a combination of several toxins could lead to greater risk of 
developing PD than a single toxin. 
2.3 Caffeine, cigarette 
Smokers and coffee drinkers have been associated with a lower risk of PD in several 
epidemiological studies. Hernan et al. conducted a meta-analytic review for the 
association between caffeine intake, smoking, and the risk of PD. Interestingly the 
cigarette smokers had 60% lower risk for the development of PD than people without a 
history of smoking (Hernan et al. 2002). Some experiments suggested that chronic nicotine 
treatment could have protective effects against the nigrostriatal neuronal cell death in 
MPTP-treated animal models. Several studies revealed that cigarette smoking inhibited 
monoamine oxidase (MAO) activity and nicotine stimulated dopamine release. As a 
result, cigarette smoking may suppress free radical generation via MAO-B-associated 
metabolism of dopamine, and be able to protect against dopaminergic cell death (Miller et 
al. 2007). Similar to cigarette smoking, coffee drinking could result in a 30% decreased risk 
of PD compared with non-coffee drinkers (Hernan et al. 2002). Chen et al reported that 
caffeine had similar effects as A2A antagonists, and attenuated MPTP toxicity via A2A 
receptor blockade (Chen et al. 2001).  
2.4 Disease process and dual hit theory 
Braak and colleagues proposed neuropathological staging in PD. They reported that the 
dorsal motor nucleus of the glossopharyngeal and vagal nerves and the anterior olfactory 
nucleus were initially affected, and subsequently the substantia nigra and locus coeruleus 
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became involved. Cortical areas showed less vulnerability, gradually becoming affected 
(Braak et al. 2003). These pathological findings suggest that the neuronal degeneration in PD 
may extend from peripheral systems, such as olfactory and autonomic systems to cortices. 
They also proposed the so-called “Dual-Hit” hypothesis, which suggests that neurotropic 
pathogens may enter the nervous system via both nasal and intestinal epithelium (Hawkes 
et al. 2007). These events may promote α-synuclein aggregation and subsequently misfolded 
α-synuclein may propagate between cells in a prion-like manner (Angot et al. 2010). By 
using cultured cell models and α-synuclein transgenic mice models, Desplats et al 
demonstrated direct neuron to neuron transmission of α-synuclein aggregates (Desplats et 
al. 2009). Actually, in the brains of PD patients who received fetal ventral mesencephalic 
transplants, grafted nigral neurons contained Lewy body-like inclusions (Li et al. 2008, 
Kordower et al. 2008). These results corroborate the hypothesis that progression of α-
synuclein aggregation relies on the same mechanisms of prion propagation. In conclusion, 
environmental factors could play important roles in the pathomechanisms of neuronal 
degeneration in sporadic PD 
3. Genetic factors and PD 
3.1 α-synuclein 
┙-synuclein is a 140-amino acid protein that is abundantly expressed throughout the brain, 
and especially in presynaptic nerve terminals. In 1997, an ┙-synuclein A53T mutation was 
isolated from an autosomal dominant PD case. Cases of sporadic PD and A53T-associated 
patients displayed similar clinical phenotypes, with the exception of a relatively earlier age 
of onset and atypical features such as cognitive decline, severe central hypoventilation, 
orthostatic hypotension, myoclonus and urinary incontinence (Polymeropoulos et al. 1997, 
Spira et al. 2001). In addition, A30P (Kruger et al. 1998) and E46K (Zarranz et al. 2004) 
mutations were also identified. Following the identification of mutations in the ┙-synuclein 
gene, multiplication of SNCA has also been identified to cause autosomal dominant familial 
PD (Ibanez et al. 2004, Chartier-Harlin et al. 2004, Nishioka et al. 2006, Ahn et al. 2008). 
Considering that ┙-synuclein protein is the major component of Lewy bodies (Spillantini et 
al. 1997), aggregation of ┙-synuclein is thought to be a key event in dopaminergic neuronal 
cell death in both SNCA-linked and sporadic PD (Lee & Trojanowski 2006). ┙-synuclein has 
a high propensity to aggregate, just like other proteins associated with neurodegenerative 
disease, such as tau, amyloid precursor protein, and poly Q proteins (Bossy-Wetzel et al. 
2004, Cookson 2005). ┙-synuclein exists in solution as an unstructured monomer, however, 
monomeric ┙-synuclein can form insoluble fibrillar aggregates with an antiparallel ┚-sheet 
structure through the formation of oligomeric forms (protofibrils). The fibrils assemble in 
vitro, and these filaments closely aggregate just like pathologic inclusions in PD or MSA 
(Cookson 2005). Fibril formation by pathogenic mutations is accelerated in vitro compared 
with the wild type (Narhi et al. 1999, Conway et al. 2000, Greenbaum et al. 2005). In several 
experimental models, including cultured cells, rodent, Drosophilae and Caenorhabditis elegans, 
pathogenic mutants also promote self-aggregation and oligomerization into protofibrils, 
compared with the wild-type protein. Some studies suggest that ┙-synuclein could 
participate in a protein degradation pathway such as the ubiquitin-proteasomal system 
(UPS) (Rideout et al. 2001, Zhang et al. 2008), and chaperone-mediated autophagy(Cuervo et 
al. 2004).  
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The functions of ┙-synuclein under normal physiological conditions remain unknown. 
However, several studies have shown that ┙-synuclein associates with synaptic vesicles and 
modulates neurotransmitter release (Jensen et al. 1998, Li et al. 2004). Electrophysiological 
study in ┙-synuclein knockout mice revealed that ┙-synuclein could act as an activity-
negative regulator of DA neurotransmission at synaptic terminals (Abeliovich et al. 2000). ┙-
synuclein is also speculated to have various other functions, such as modulation of tyrosine 
hydroxylase (TH) activation (Perez et al. 2002), inhibition of vesicular monoamine 
transporter-2 (VMAT2) activity (Guo et al. 2008), and interaction with septin4, which have 
been implicated in exocytosis (Ihara et al. 2007). Recently, Cooper and colleagues reported 
that ┙-synuclein blocked endoplasmic reticulum (ER)-to-Golgi vesicular trafficking, and 
induced ER stress followed by cell death (Cooper et al. 2006). In addition, ┙-synuclein may 
interact with the synaptic membrane through lipid rafts (Fortin et al. 2004, Kubo et al. 2005), 
which are known to be a signaling platform for cellular functions such as signal 
transduction, membrane trafficking and cytoskeletal organization. These data indicate that 
┙-synuclein plays important roles in vesicle sorting and regulation of catecholamine 
metabolism in dopaminergic neurons. 
3.2 LRRK2 
LRRK2 mutations were identified as the causative gene for PARK8-linked familial PD 
(Paisan-Ruiz et al. 2004), (Zimprich et al. 2004). Some screening studies reported that LRRK2 
mutations were identified not only in familial PD but also in sporadic PD. Since then, LRRK2 
mutations seem to be the most frequent cause of autosomal dominantly-inherited familial 
PD (Lesage et al. 2006, Ozelius et al. 2006). R1628P and G2385R are polymorphic mutations 
and have been demonstrated as risk factors for sporadic PD in Asian populations (Di Fonzo 
et al. 2006, Funayama et al. 2007). The clinical features of patients with LRRK2 mutations 
essentially resemble sporadic PD with good response to levodopa. Pathological studies of 
autopsy cases with I1371V, A1441C, Y1699C, G2019S, and I2020T mutations have revealed 
neuronal cell loss accompanied by Lewy bodies indistinguishable from those of sporadic 
PD. Some individuals display pleomorphic pathologies, including synucleinopathy, 
tauopathy, TDP-43 proteinopathy, substantia nigral neuronal loss alone, and neuronal loss 
with nuclear ubiquitin inclusions (Zimprich et al. 2004, Covy et al. 2009). Although some 
antibodies against the functional domain fail to detect Lewy bodies, other antibodies 
directed against the N-terminal and C-terminal residues are able to stain Lewy bodies. Thus, 
there is controversy as to whether LRRK2 is a component of Lewy bodies. LRRK2 also 
colocalizes with tau-positive inclusions in fronto-temporal dementia with MAPT N279K 
mutation (Miklossy et al. 2007). Considering this pleomorphic pathology, LRRK2 seems to 
be involved in disease-modifying pathways in various neurodegenerative diseases.  
The LRRK2 protein is a 2527 amino acid polypeptide (~280 kDa), consisting of leucine-rich 
repeats (LRR), Ras of complex proteins (Roc) followed by the C-terminal of Roc (COR), 
mitogen-activated protein kinase kinase kinase (MAPKKK) and WD40 domains (Mata et al. 
2006). LRRK2 protein belongs to the ROCO protein family. LRRK2 proteins localize in the 
cytoplasm and membranous organelles, including ER, Golgi apparatus, early endosomes, 
lysosomes, synaptic vesicles, mitochondria, and the plasma membrane (Hatano et al. 2007). 
We found LRRK2 bound to lipid rafts within the synaptosomes (Hatano et al. 2007). Several 
results suggest that LRRK2 also interacts with the Rab family and presynaptic proteins, and 
modulates the membrane trafficking system.  
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An in vitro phosphorylation assay using thin-layer chromatography revealed that LRRK2 
might also function as a serine/threonine kinase (West et al. 2007). The frequent LRRK2 
G2019S and adjacent I2020T mutations are located within the kinase domain and exhibit 
increased activity (West et al. 2005, Gloeckner et al. 2006). The kinase activity could be 
regulated by GTP via the intrinsic GTPase Roc domain (Smith et al. 2006, West et al. 2007). 
Considering that at least some of the mutations alter the kinase activity and are neurotoxic, 
misregulated kinase activity may explain the core damaging effect of LRRK2 in neurons. 
Actually, several groups reported that LRKK2 is able to modulate several signal 
transduction pathways, such as the ERK1/2, TNFα/FasL and Wnt signaling pathways 
(Berwick & Harvey 2011), and the microRNA pathway, which regulates protein synthesis 
(Gehrke et al. 2010). The interaction between LRRK2 and parkin is also reported, but there is 
no evidence to associate LRRK2 with other genes, such as ┙-synuclein, tau, and DJ-1 (Smith 
et al. 2005). Further investigations may reveal how LRRK2 participates in pathways of other 
PARK gene-related dopaminergic neuronal degeneration. 
3.3 PINK1/Parkin pathway 
Mutations in parkin were identified as the cause of autosomal recessive early onset PD 
(EOPD) (Kitada et al. 1998), followed by mutations in DJ-1 (Bonifati et al. 2003), and PINK1 
(Valente et al. 2004, Hatano et al. 2004). PARK2-linked EOPD is characterized by a 
spontaneous improvement after sleep or a nap, diurnal fluctuation, some dystonic features 
which are predominantly in the foot, good response to levodopa, early onset (average age of 
onset is in the twenties), no dementia, no autonomic failure, and lack of Lewy bodies 
(Yamamura et al. 1973, Mori et al. 1998). The clinical features of PARK2-linked EOPD are 
distinguishable from those of patients with the common form of PD. Pathological studies in 
patients with PARK2-linked EOPD have shown that the substantia nigra and locus 
coeruleus exhibit selective degeneration with gliosis (Mori et al. 1998). Other pigmented 
neurons in these regions contain traces of melanin pigments, and the cell cytoplasm is 
scanty compared with that of normal individuals without neurodegenerative disorders. 
Although the brain tissue of two cases, which were positive for parkin mutation showed the 
presence of Lewy bodies (Farrer et al. 2001, Pramstaller et al. 2005), they are generally absent 
in PARK2-mutation brains.  
Parkin protein is linked to the ubiquitin-proteasome pathway as a ubiquitin ligase (E3) 
(Shimura et al. 2000). Most Lewy bodies also stain strongly for ubiquitin, which is highly 
involved in the protein degradation system. Furthermore, the collaboration between parkin 
and PINK1 could be associated with mitochondrial quality control systems (Geisler et al. 
2010, Vives-Bauza et al. 2010, Narendra et al. 2010, Kawajiri et al. 2010, Matsuda et al. 2010). 
Parkin-deficient Drosophila exhibit mitochondrial structural alterations in testes and muscle 
tissue (Greene et al. 2003). PINK1-deficient Drosophila also exhibited degeneration of flight 
muscles and dopaminergic neuronal cells accompanied by mitochondrial abnormality, and 
share phenotypic similarity with parkin-deficient Drosophila. Overexpression of parkin 
reversed the muscle damage in PINK1-deficient Drosophila, but PINK1 overexpression could 
not reverse the parkin-null-linked damage (Clark et al. 2006, Park et al. 2006). Furthermore, 
mitochondrial abnormalities in PINK1- or parkin-deficient Drosophila were reversed by 
knockdown of Mitofusin (Mfn), Optic atrophy 1 (Opa1), or overexpression of Dynamin-related 
protein1 (Drp1), which participate in mitochondrial fusion and fission (Deng et al. 2008). 
These findings suggest that PINK1 might associate upstream of parkin to regulate 
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mitochondrial dynamics. The interaction between PINK1 and parkin was also analyzed by 
using a cultured cell system (Shiba et al. 2009). Narendra and colleagues (2010) reported 
accumulation of parkin in mitochondria impaired by carbonyl cyanide m-
chlorophenylhydrazone. Such accumulation promotes the selective autophagy of damaged 
mitochondria (mitophagy). Several groups have recently shown that PINK1 might be 
required for parkin-mediated mitophagy (Geisler et al. 2010; Vives-Bauza et al. 2010; 
Narendra et al. 2010; Kawajiri et al. 2010; Matsuda et al. 2010). We reported that parkin 
relocates cytoplasm to damaged mitochondria in a membrane potential-dependent manner 
(Matsuda et al.2010). PINK1 plays a critical role in recruiting parkin to mitochondria with 
low membrane potential to initiate the autophagic degradation of damaged mitochondria. 
Pathogenic parkin mutations affect mitochondrial localization. Therefore, loss of the 
association between parkin and damaged mitochondria could lead to nigral cell death in 
PARK2-linked EOPD. Immunoprecipitation using anti-LC3 antibodies revealed the direct 
interaction between PINK1 and endogenous LC3 (Kawajiri et al. 2010). These results suggest 
that mitochondrial degradation by the PINK1/Parkin pathway is dependent on 
mitochondrial autophagic activity. Geisler et al. (2010) also reported that the kinase activity 
of PINK1 in mitochondria might be needed to induce translocation of parkin to depolarized 
mitochondria. Parkin modified VDAC1 via Lys27 poly-ubiquitylation, and promoted 
autophagic degradation of damaged mitochondria. Interestingly, they also revealed that the 
autophagic adaptor p62/SQSTM1 is recruited to mitochondrial clusters and could be 
associated with PINK1/Parkin-mediated mitophagy. Funayama et al. identified PD patients 
carrying both parkin and PINK1 mutations, whose onset age was younger than that of 
patients with the same parkin mutation alone. The presence of digenic mutations, such as 
parkin plus PINK1 mutations, suggests that a PINK1 mutation could influence the clinical 
symptoms of parkin-linked PD (Funayama et al. 2008). However, Kitada and colleagues 
(Kitada et al. 2009) reported that triple knockout of Parkin, PINK1, and DJ-1 resulted in 
normal morphology and numbers of dopaminergic and noradrenergic neurons in the 
substantia nigra and locus coeruleus. Therefore, understanding the PINK1/Parkin pathway 
underlying the mitochondrial dynamics helps clarify the pathomechanics in PD. 
4. Conclusion  
The pathological mechanisms and causes of PD remain largely unknown. Most PD patients 
have not been associated with a particular genetic background or certain exposure of 
environmental toxins. However, Japanese and European groups performed genome-wide 
association studies and revealed that the ┙-synuclein locus, the MAPT locus, the LRRK2 
locus, the BST1 locus, and 1q32 (PARK16) may be genetic risk factors for PD (Satake et al. 
2009, Simon-Sanchez et al. 2009). Although the ┙-synuclein locus, LRRK2 locus, and 
PARK16 are confirmed as genetic risk factors for PD across populations, BST1 and MAPT 
may be risk loci correlated with ethnic differences. Conversely, ┙-synuclein is involved in 
the virulent effects of the environmental toxin MPTP. High mRNA and protein levels of ┙-
synuclein have been described in the brains of MPTP-treated mice (Vila et al. 2000). 
Although ┙-synuclein-deficient mice exhibited marked resistance to MPTP-induced 
degeneration of dopamine neurons (Dauer et al. 2002), some lines of ┙-synuclein transgenic 
mice have exhibited increased sensitivity to MPTP (Nieto et al. 2006, Yu et al. 2008). These 
results also suggest that various genetic-environmental interactions may have influences on 
dopaminergic neuronal metabolism and kinetics, such as signal transduction, vesicle 
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transport, autophagy (mitophagy), and mitochondrial stress (Figure 2). In addition, a prion-
like transmission of ┙-synuclein may trigger the development of nigral degeneration in PD. 
Taken together, the new findings based on the interaction between familial PD-related 
proteins and environmental factors could shed light on the pathomechanisms for PD.  
 
 
Fig. 2. Summary of pathogenetic factors involved in Parkinson’s disease (PD). Recent 
evidence indicated that the PINK1/Parkin pathway participates in mitochondrial removal 
via autophagy (mitophagy). LRRK2 may associate with cell signaling pathways and the 
membrane trafficking system. Several environmental factors, such as MPTP, paraquat, and 
rotenone are known as mitochondrial toxins. In addition, a prion-like transmission of ┙-
synuclein may trigger the development of nigral degeneration in PD. 
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